Clinical Trial
doi: 10.1038/bmt.2008.404.
Epub 2008 Dec 15.
The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans
- PMID: 19079309
- DOI: 10.1038/bmt.2008.404
Item in Clipboard
Clinical Trial
The effect of administration order of BU and CY on toxicity in hematopoietic SCT in humans
Bone Marrow Transplant.
2009 Jun.
No abstract available
Comment on
-
The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.Bone Marrow Transplant. 2008 May;41(10):895-904. doi: 10.1038/sj.bmt.1705996. Epub 2008 Jan 28. Bone Marrow Transplant. 2008. PMID: 18223695
Similar articles
-
[Efficacy and toxicity of intravenous busulfan-based conditioning before allogeneic peripheral blood stem cell transplantation for leukemia].Ai Zheng. 2007 Aug;26(8):914-8. Ai Zheng. 2007. PMID: 17697559 Chinese.
-
Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT.Bone Marrow Transplant. 2011 Mar;46(3):344-9. doi: 10.1038/bmt.2010.137. Epub 2010 Jun 14. Bone Marrow Transplant. 2011. PMID: 20548339
-
Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma.Bone Marrow Transplant. 1997 Apr;19(8):777-81. doi: 10.1038/sj.bmt.1700733. Bone Marrow Transplant. 1997. PMID: 9134168
-
Treosulfan-based conditioning before hematopoietic SCT: more than a BU look-alike.Bone Marrow Transplant. 2012 Jan;47(1):5-14. doi: 10.1038/bmt.2011.88. Epub 2011 Apr 11. Bone Marrow Transplant. 2012. PMID: 21478921 Review.
-
Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation.Bone Marrow Transplant. 2003 Dec;32(12):1175-9. doi: 10.1038/sj.bmt.1704274. Bone Marrow Transplant. 2003. PMID: 14647272 Review.
Cited by
-
Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):901-923. doi: 10.1080/17425255.2017.1360277. Epub 2017 Aug 17. Expert Opin Drug Metab Toxicol. 2017. PMID: 28766962 Free PMC article. Review.
-
Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.Bone Marrow Transplant. 2016 Sep;51(9):1265-7. doi: 10.1038/bmt.2016.109. Epub 2016 Apr 25. Bone Marrow Transplant. 2016. PMID: 27111042 No abstract available.
-
Evaluation of Reversed Administration Order of Busulfan (BU) and Cyclophosphamide (CY) as Conditioning on Liver Toxicity in Allogenic Hematopoietic Stem Cell Transplantation (ALL-HSCT).Int J Hematol Oncol Stem Cell Res. 2020 Jul 1;14(3):171-176. doi: 10.18502/ijhoscr.v14i3.3725. Int J Hematol Oncol Stem Cell Res. 2020. PMID: 33024523 Free PMC article.
-
Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.Biol Blood Marrow Transplant. 2013 Jul;19(7):1033-9. doi: 10.1016/j.bbmt.2013.04.005. Epub 2013 Apr 10. Biol Blood Marrow Transplant. 2013. PMID: 23583825 Free PMC article. Clinical Trial.
-
A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies.Int J Clin Pharm. 2015 Feb;37(1):44-52. doi: 10.1007/s11096-014-0036-5. Epub 2014 Nov 29. Int J Clin Pharm. 2015. PMID: 25432692
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
